Zilganersen

Here's what you may have missed since our last episode.

First, on September 3rd, the FDA approved Ionis' Zilganersen injection marketed as Zanvastrof for the treatment of Alexander disease in pediatric and adult patients.

With this decision, Zilganersen becomes the first FDA approved treatment for Alexander disease and the first therapy to directly target the protein buildup driving the condition.

A week later, on September 10th, the FDA granted priority review to Genotex Satralizumab for MOG, Antibody-Associated Disease, or MOGAD, a rare autoimmune central nervous system disorder.

If approved, Satralizumab would become the first and only disease-modifying therapy for MOGAD, with an FDA decision date expected January 10th, 2027.